CDP niacin, 1975 trial summary

A randomised clinical trial investigating the effect of niacin versus placebo in Hommes, de 30 à 64 ans

        Z

NCT00000482?acronym=    JAMA 1975;231:360-381  



Studied treatment Niacin 3 mg/j
Control treatment Placebo



Patients Hommes, de 30 à 64 ans
Group sizes1119 / 2789
Inclusion criteriaIDM < 3 mois
Exclusion criteriaAggravation récente des maladies coronariennes



Blindness Double aveugle Inclusion period
Follow-up duration 6.2 ans Centers
Lost to FU ND geographical localisation
Primary endpoint Mortalité totale Design Bras parallèles
ArretTrt1ND



EndpointX1N1X0N0TE95% CI IDM non fatal 114 1119 386 2789 0,74[0,59; 0,92] Mortalité coronarienne 203 1119 535 2789 0,95[0,79; 1,13] AVC fatal et non fatal - 1119 - 2789 no data Evènements coronariens 287 1119 839 2789 0,85[0,73; 1,00] Mortalité toute cause 273 1119 709 2789 0,96[0,82; 1,13] Mortalité par cancer 9 1119 24 2789 0,93[0,43; 2,02]0,22,01,0

The Coronary Drug Project Research group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381     [PMID: 1088963]   link to pdf   add to Mendeley  

ClinicalTrial.gov record NCT00000482?acronym=



Registering number NCT00000482?acronym= (see trial on clinicaltrials.gov)
Code Name

 

All trials of niacin

Appears in following systematic reviews: